NASDAQ · CMPS
COMPASS Pathways Plc American Depository Shares
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CMPS: Nov 03, 2026
COMPASS Pathways Plc American Depository Shares is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.34. The reported EPS for the same quarter last year was $-0.38.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.34 | $-0.06 | $-0.43 | 6 |
| Dec 2026 | $-0.38 | $-0.09 | $-0.48 | 7 |
| Mar 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Jun 2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · MarketBeat · The Motley Fool · RTTNews- Fintel · Oct 23, 10:20 AM EDTCOMPASS Pathways plc – Depositary Receipt Price Target Increased by 10.49% to $24.76The average one-year price target for COMPASS Pathways plc – Depositary Receipt (NASDAQGS:CMPS) (BMV:CMPS N) has been revised to $24.76 / share. This is an increase of 10.49% from the prior estimate of $22.41 dated September 29, 2026. These figures represent aggregate analyst tar
- MarketBeat · Sep 24, 8:02 PM EDTCompass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 LaunchThese 3 Psychedelic Stocks Activated After Trump's Executive OrderCompass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a
- MarketBeat · Sep 22, 5:02 PM EDTCompass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression DataThese 3 Psychedelic Stocks Activated After Trump's Executive OrderCompass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilo
- MarketBeat · Sep 22, 3:02 PM EDTCompass Pathways Eyes 2027 COMP360 Launch as FDA Review AdvancesThese 3 Psychedelic Stocks Activated After Trump's Executive OrderCompass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potenti
- MarketBeat · Sep 22, 2:02 AM EDTCompass Pathways Eyes 2027 COMP360 Launch as FDA Filing NearsThese 3 Psychedelic Stocks Activated After Trump's Executive OrderCompass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential comm
- The Motley Fool · Aug 12, 1:43 PM EDTCOMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 12, 12:04 PM EDTCompass Pathways Targets 2027 COMP360 Launch as FDA Filing AdvancesThese 3 Psychedelic Stocks Activated After Trump's Executive OrderCompass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this yea
- MarketBeat · Aug 5, 9:04 AM EDTCompass Pathways Q2 Earnings Call HighlightsThese 3 Psychedelic Stocks Activated After Trump's Executive OrderCompass Pathways (NASDAQ:CMPS) said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following positive Phase III
- The Motley Fool · Jul 29, 5:20 AM EDTEli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.One of Cathie Wood's funds just sold some AtaiBeckley shares.
- RTTNews · Jul 27, 6:13 AM EDT5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%(RTTNews) – "If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes." – Warren Buffett. The Oracle of Omaha's timeless advice reminds us that patience is one of the key principles of investing.
- The Motley Fool · Jul 23, 9:05 AM EDTEli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.Eli Lilly is going to buy a psychedelic drug biotech called AtaiBeckley.
- MarketBeat · Jul 10, 3:02 AM EDTCompass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds UpThese 3 Psychedelic Stocks Activated After Trump's Executive OrderCompass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depre
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for COMPASS Pathways Plc American Depository Shares from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.